Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator

BioMetals

Volumn 28, Issue 2, 2015, Pages 279-292

  Toblli, Jorge E ^a   Cao, Gabriel ^a   Angerosa, Margarita ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Apoptosis; Intravenous iron; Iron sucrose; Nitrosative stress; Non clinical

Indexed keywords

FERRIC ION; FERRIC OXIDE, SACCHARATED; INTERLEUKIN 6; IRON(III)-HYDROXIDE SUCROSE COMPLEX; REACTIVE NITROGEN SPECIES; SACCHARIC ACID; SUCROSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; APOPTOSIS; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; INTRADERMAL DRUG ADMINISTRATION; LIVER; MALE; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; FEMALE; FERRIC COMPOUNDS; GLUCARIC ACID; INJECTIONS, INTRADERMAL; INTERLEUKIN-6; LIVER; MALE; RATS, SPRAGUE-DAWLEY; REACTIVE NITROGEN SPECIES; STRESS, PHYSIOLOGICAL; SUCROSE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939974062     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-015-9822-3     Document Type: Article

References (59)

1. Adams ET, Schwartz KA (1993) Iron-induced myocardial and hepatic lysosomal abnormalities in the guinea pig. Toxicol Pathol 21:321-326
2. Auerbach M, Ballard H (2010) Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010:338-347. doi: 10.1182/asheducation-2010.1.338
3. Bailie GR, Schuler C, Leggett RE, Li H, Li HD, Patadia H, Levin R (2013) Oxidative effect of several intravenous iron complexes in the rat. Biometals 26:473-478. doi: 10.1007/s10534-013-9632-4
4. Barbouti A, Amorgianiotis C, Kolettas E, Kanavaros P, Galaris D (2007) Hydrogen peroxide inhibits caspase-dependent apoptosis by inactivating procaspase-9 in an iron-dependent manner. Free Radic Biol Med 43:1377-1387. doi: 10.1016/j.freeradbiomed.2007.06.020
5. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, Antoni G, Långström B, Danielson BG (1999) Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 104:296-302
6. Beshara S, Sorensen J, Lubberink M, Tolmachev V, Langstrom B, Antoni G, Danielson BG, Lundqvist H (2003) Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 120:853-859
7. Brissot P, Ropert M, Le LC, Loreal O (2012) Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 1820:403-410. doi: 10.1016/j.bbagen.2011.07.014
8. Brunk UT, Neuzil J, Eaton JW (2001) Lysosomal involvement in apoptosis. Redox Rep 6:91-97. doi: 10.1179/135100001101536094
9. Chandler G, Harchowal J, Macdougall IC (2001) Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 38:988-991
10. Danielson BG (2004) Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 15(Suppl 2):S93-S98. doi: 10.1097/01.ASN.0000143814.49713.C5
11. Dimitriou E, Kairis M, Sarafidou J, Michelakakis H (2000) Iron overload and kidney lysosomes. Biochim Biophys Acta 1501:138-148
12. Drapier JC, Hirling H, Wietzerbin J, Kaldy P, Kuhn LC (1993) Biosynthesis of nitric oxide activates iron regulatory factor in macrophages. EMBO J 12:3643-3649
13. Ehmann F, Sakai-Kato K, Duncan R, Perez de la Ossa DH, Pita R, Vidal JM, Kohli A, Tothfalusi L, Sanh A, Tinton S, Robert JL, Silva LB, Amati MP (2013) Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond) 8:849-856. doi: 10.2217/nnm.13.68
14. EMA (2013) Draft: Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product, EMA/CHMP/SWP/620008/2012. European Medicines Agency, London
15. Fergelot P, Ropert-Bouchet M, Abgueguen E, Orhant M, Radosavljevic M, Grimber G, Jouan H, Le Gall JY, Mosser J, Gilfillan S, Bahram S (2002) Iron overload in mice expressing HFE exclusively in the intestinal villi provides evidence that HFE regulates a functional cross-talk between crypt and villi enterocytes. Blood Cells Mol Dis 28:348-360
16. Geisser P, Baer M, Schaub E (1992) Structure/histotoxicity relationship of parenteral iron preparations. Drug Res 42:1439-1452
17. Goligorsky MS, Brodsky SV, Noiri E (2002) Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int 61:855-861. doi: 10.1046/j.1523-1755.2002.00233.x
18. Harris DC, Tay C, Nankivell BJ (1994) Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol 21:73-81
19. Ishizaka N, Saito K, Noiri E, Sata M, Mori I, Ohno M, Nagai R (2004) Iron dextran causes renal iron deposition but not renal dysfunction in angiotensin II-treated and untreated rats. Nephron Physiol 98:107-113. doi: 10.1159/000081559
20. Kadkhodaee M, Gol A (2004) The role of nitric oxide in iron-induced rat renal injury. Human Exp Toxicol 23:533-536
21. Kim YM, Chung HT, Simmons RL, Billiar TR (2000) Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem 275:10954-10961
22. Kim KM, Kim PK, Kwon YG, Bai SK, Nam WD, Kim YM (2002) Regulation of apoptosis by nitrosative stress. J Biochem Mol Biol 35:127-133
23. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S (2013) The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med 65C:1174-1194. doi: 10.1016/j.freeradbiomed.2013.09.001
24. Lee ES, Park BR, Kim JS, Choi GY, Lee JJ, Lee IS (2013) Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin 29:141-147. doi: 10.1185/03007995.2012.760444
25. Lu N, Li X, Li J, Xu W, Li H, Gao Z (2011) Nitrative and oxidative modifications of enolase are associated with iron in iron-overload rats and in vitro. J Biol Inorg Chem 16:481-490. doi: 10.1007/s00775-010-0747-6
26. Ludwiczek S, Aigner E, Theurl I, Weiss G (2003) Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101:4148-4154. doi: 10.1182/blood-2002-08-2459
27. Macdougall IC, Geisser P (2013) Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 7:9-22
28. Martines AM, Masereeuw R, Tjalsma H, Hoenderop JG, Wetzels JF, Swinkels DW (2013) Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat Rev Nephrol 9:385-398. doi: 10.1038/nrneph.2013.98
29. Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, Crespo R, Ramirez R, Aljama P (2012) Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 27:2465-2471. doi: 10.1093/ndt/gfr711
30. Mattson DL, Maeda CY, Bachman TD, Cowley AW Jr (1998) Inducible nitric oxide synthase and blood pressure. Hypertension 31:15-20
31. Myers BM, Prendergast FG, Holman R, Kuntz SM, LaRusso NF (1991) Alterations in the structure, physicochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest 88:1207-1215. doi: 10.1172/JCI115423
32. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004a) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271-1276. doi: 10.1172/JCI20945
33. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004b) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090-2093. doi: 10.1126/science.1104742
34. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315-424. doi: 10.1152/physrev.00029.2006
35. Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A (2011) Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 26:3262-3267. doi: 10.1093/ndt/gfr024
36. Schellekens H, Klinger E, Muhlebach S, Brin JF, Storm G, Crommelin DJ (2011) The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 59:176-183. doi: 10.1016/j.yrtph.2010.09.021
37. Sliskovic I, Mutus B (2006) Reversible inhibition of caspase-3 activity by iron(III): potential role in physiological control of apoptosis. FEBS Lett 580:2233-2237. doi: 10.1016/j.febslet.2006.03.031
38. Stein J, Dignass A, Chow KU (2012) Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 28:241-243. doi: 10.1185/03007995.2011.651527
39. Toblli JE, Stella I, de Cavanagh E, Angerosa M, Inserra F, Ferder L (1999) Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Hypertension 33:225-231
40. Toblli JE, Cao G, DeRosa G, Forcada P (2005) Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril. Heart 91:80-86. doi: 10.1136/hrt.2003.022707
41. Toblli JE, Cao G, Oliveri L, Angerosa M (2009a) Differences between original intravenous iron sucrose and iron sucrose similar preparations. Drug Res 59:176-190. doi: 10.1055/s-0031-1296383
42. ®, and potential implications. Port J Nephrol Hypert 23:53-63
43. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF (2009c) Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 24:2384-2391. doi: 10.1093/ndt/gfp103
44. Toblli JE, Cao G, Olivieri L, Angerosa M (2010a) Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 25:3631-3640. doi: 10.1093/ndt/gfq260
45. Toblli JE, Cao G, Rivas C, Munoz M, Giani J, Dominici F, Angerosa M (2010b) Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens 28:1007-1019
46. Toblli JE, Cao G, Giani J, Dominici F, Angerosa M (2011a) Different effects of European iron sucrose similar preparations and originator iron sucrose on nitrosative stress, apoptosis, oxidative stress, biochemical and inflammatory markers in rats. Abstract, XLVIII ERA-EDTA Congress
47. Toblli JE, Cao G, Oliveri L, Angerosa M (2011b) Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Drug Res 61:399-410
48. Toblli JE, Cao G, Oliveri L, Angerosa M (2011c) Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model. Drug Res 61:553-565
49. Toblli JE, Cao G, Oliveri L, Angerosa M (2012) Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 11:66-78
50. Toblli JE, Cao G, Giani JF, Dominici FP, Angerosa M (2014) Comparison of nitrosative stress and apoptosis in non-anemic healthy rats after intravenous ferumoxytol, iron isomaltoside 1000, iron dextran, iron sucrose, and ferric carboxymaltose administration. Drug Res (in press)
51. Tunçtan B, Korkmaz B, Yildirim H, Tamer L, Atik U, Buharalýoglu K (2005) Increased production of nitric oxide contributes to renal oxidative stress in endotoxemic rat. Am J Inf Dis 1:111-115
52. USP (2008) Iron sucrose injection, official monograph in: The United States Pharmacopeia. United States Pharmacopeial Convention, Rockville, MD, US 31:2449-2451
53. van Wyck D, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19:561-565
54. Wang J, Chen G, Pantopoulos K (2005) Nitric oxide inhibits the degradation of IRP2. Mol Cell Biol 25:1347-1353. doi: 10.1128/MCB.25.4.1347-1353.2005
55. Wardrop SL, Watts RN, Richardson DR (2000) Nitrogen monoxide activates iron regulatory protein 1 RNA-binding activity by two possible mechanisms: effect on the [4Fe-4S] cluster and iron mobilization from cells. Biochemistry 39:2748-2758
56. Weiss G, Goossen B, Doppler W, Fuchs D, Pantopoulos K, Werner-Felmayer G, Wachter H, Hentze MW (1993) Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J 12:3651-3657
57. Yang F, Liu XB, Quinones M, Melby PC, Ghio A, Haile DJ (2002) Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem 277:39786-39791. doi: 10.1074/jbc.M201485200
58. Youn P, Kim S, Ahn JH, Kim Y, Park JD, Ryu DY (2009) Regulation of iron metabolism-related genes in diethylnitrosamine-induced mouse liver tumors. Toxicol Lett 184:151-158. doi: 10.1016/j.toxlet.2008.11.002
59. Zarjou A, Bolisetty S, Joseph R, Traylor A, Apostolov EO, Arosio P, Balla J, Verlander J, Darshan D, Kuhn LC, Agarwal A (2013) Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest 123:4423-4434. doi: 10.1172/JCI67867